Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review

A Correction to this article was published on 28 September 2021

This article has been updated


Kratom is a legal, widely available substance that contains opioid agonist alkaloids. Due to the marketing of kratom as an opioid alternative for treatment of pain, anxiety, depression, or to reduce opioid withdrawal symptoms, the use of kratom has increased among persons in the USA including pregnant women. This systematic review of the peer-reviewed literature regarding kratom in relation to maternal and infant outcomes resulted in analysis of six case reports of prenatal kratom exposure. Maternal and infant withdrawal from kratom exposure was described in each case, resulting in pharmacologic treatment for both mothers and infants.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Prisma flow diagram.

Similar content being viewed by others

Change history


  1. Khey DN, Stogner JM, Miller BL. Emerging trends in drug use and distribution. New York, NY: Springer; 2014.

  2. O’Neill-Dee C, Spiller HA, Casavant MJ, Kistamgari S, Chounthirath T, Smith TA. Natural psychoactive substance-related exposures reported to United States poison control centers, 2000–2017. Clin Toxicol. 2019.

  3. National Center for Biotechnology Information. Mitragynine. PUBCHEM database. National Center for Biotechnology Information. 2021.

  4. Raffa RB, Pergolizzi JV, Taylor R, Ossipov MH. NEMA Research Group. Natur’s first “atypical opioid”: kratom and mitragynines. J Clin Pharmacol. 2018;43:437–41.

  5. Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull. 2004;52:916–28.

    Article  CAS  Google Scholar 

  6. Griffin OH III, Daniels JA, Gardner EA. Do you get what you paid for? An examination of products advertised as kratom. J Psychoactive Drugs. 2016;1–6.

  7. Lydecker AG, Sharma A, McCurdy CR, Avery BA, Babu KM, Boyer EW. Suspected adulteration of commercial kratom products with 7-hydro-xymitragynine. J Med Toxicol. 2016:12:341–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Leg Med. 2016;130:127–38.

    Article  Google Scholar 

  9. Lee J, Park J, Go A, Moon H, Kim S, Jung S, et al. Urine multi-drug screening with GC-MS or LC–MS-MS using SALLE-hybrid PPT/SPE. J Anal Toxicol. 2018;42:617–24.

    Article  CAS  PubMed  Google Scholar 

  10. Sharma A, Kamble SH, Leon F, Chear HJY, King TL, Bethold EC, et al. Simultaneous quantification of ten key kratom alkaloids in Mitragyna speciose lef actrates and commercial products by untra-performance liquid chromatography-tandem mass spectrometry. Drug Test Anal. 2019;11:8.

    Article  Google Scholar 

  11. Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. Kratom (Mitragyna speciose): user demographics, use patterns and implications for the opioid epidemic. Drug Alcohol Depend. 2020;208.

  12. Singh D, Chear JY, Narayanan S, Leon F, Sharma A, McCurdy R, et al. Patterns and reasons for kratom (Mitragyna speciose) use among current and former opioid poly-drug users. J Ethnopharmacol. 2020;249.

  13. Smith K, Lawson T. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend. 2017;180:340–8.

    Article  PubMed  Google Scholar 

  14. Boyer EW, Baby KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragyna speciose Korth). Addiction. 2008;103:2145–57.

    Article  Google Scholar 

  15. Grundmann O. Patterns of kratom use and health impact in the US—results from an online survey. Drug Alcohol Depend. 2017;176:63–70.

    Article  PubMed  Google Scholar 

  16. Smith KE, Lawson T. Prevalence and motivations of kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend. 2017;180:340–8.

    Article  PubMed  Google Scholar 

  17. Coe MA, Pilllitteri JL, Sembower MA, Gerlach KK, Henningfield JE. Kratom as a substitute for opioids: results from an online survey. Drug Alcohol Depend. 2019;202:24–32.

    Article  CAS  PubMed  Google Scholar 

  18. Saref A, Suraya S, Singh D, Grundmann O, Narayanan S, Swogger MT, et al. Self-reported prevalence and severity of opioid and kratom (Mitragyna speciose Korth) side effects. J Ethnopharmacol. 2019;238.

  19. US Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse. US Food and Drug Administration. 2018.

  20. FDA. Statement from FDA Commissioner Scott Gottlieb, M.D., on new warning letters FDA is issuing to companies marketing kratom with unproven medical claims; and the agency’s ongoing concerns about kratom. FDA; 2018.

  21. U.S. Food and Drug Administration. FDA investigates multistate outbreak of salmonella infections linked to products reported to contain kratom. U.S. Food and Drug Administration. 2018.

  22. Prozioleck WC, Avery BA, Boyer EW, Grundmann O, Henningfield JE, Kruegel AC, et al. Kratom policy: the challenge of balancing therapeutic potential with public safety. Int J Drug Policy. 2019;70:70–7.

    Article  Google Scholar 

  23. Davidson L, Rawat M, Stojanovski S, Chandrasekharan P. Natural drugs, not so natural effects: neonatal abstinence syndrome secondary to ‘kratom’. J Neonatal-Perinat Med. 2019;12:109–12.

    Article  CAS  Google Scholar 

  24. Mackay L, Abrahams R. Novel case of maternal and neonatal kratom dependence and withdrawal. Can Fam Phys. 2018;64:121–2.

    Google Scholar 

  25. Murthy P, Clark D. An usual cause for neonatal abstinence syndrome. Pediatr Child Health. 2019;24:12–14.

    Article  Google Scholar 

  26. Eldridge WB, Foster C, Wyble L. Neonatal abstinence syndrome due to maternal kratom use. Pediatrics. 2018;142:e20181839.

    Article  PubMed  Google Scholar 

  27. Smid MC, Charles JE, Gordon AJ, Wright TE. Opioids case report use of kratom, an opioid-like traditional her, in pregnancy. Obstet Gynecol. 2018;132:926–8.

    Article  PubMed  Google Scholar 

  28. Loudin S, Murray S, Prunty L, Davies T, Evans J, Werthammer J. An atypical withdrawal syndrome in neonates prenatally exposed to gabapentin and opioids. J Pediatr. 2017;181:286–8.

    Article  CAS  Google Scholar 

  29. Bastiaens L, Galus J, Mazur C. Abuse of gabapentin is associated with opioid addiction. Psychiatr Q. 2016;87:763–7.

    Article  PubMed  Google Scholar 

  30. Farah T. Fears about kratom use during pregnancy are overblown. 2018.

  31. Wright ME, Temples HS. I do love my baby: stories of mothers with addiction and recovery. Columbia, SC: Amazon KDP publishing; 2019.

  32. Saingam D, Assanangkornchai S, Geater AF, Lerkiatbundit S. Validation of krathom (Mitragyna speciose Korth.) dependence scale (KDS): a dependence screen for internationally emerging psychoactive substance. Subst Abus. 2014;35:276–83.

    Article  PubMed  Google Scholar 

Download references


The project was partially supported by the Clemson Creative Inquiry Program.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Mary Ellen Wright.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: Madison Sherbondy has been added to the author list.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wright, M.E., Ginsberg, C., Parkison, A.M. et al. Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review. J Perinatol 41, 1236–1243 (2021).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links